Indegene
Indian multinational company From Wikipedia, the free encyclopedia
Indegene Limited is an Indian company that provides research and commercialization services to biopharmaceutical and healthcare enterprises.[5][6][7] Based in Bangalore, the company provides consulting in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics.[8][9]
 | This lead contains promotional content. (August 2021) |
 | |
| Formerly | Indegene Lifesystems Private Limited (1998–2016) Indegene Private Limited (2016–2022) |
|---|---|
| Company type | Public |
| Industry | Pharmaceutical consultancy[1] |
| Founded | 1998 |
| Founders | Rajesh Nair Manish Gupta Sanjay Parikh Anand Kiran Gaurav Kapoor |
| Headquarters | , India |
Area served | Worldwide |
Key people | Manish Gupta (CEO)[2] |
| Revenue | ₹2,589 crore (US$300 million) (FY24)[3] |
| ₹584 crore (US$68 million) (FY24)[3] | |
| ₹336 crore (US$39 million) (FY24)[3] | |
| Owners |
|
Number of employees | 5,081 (March 2024)[3] |
| Website | www |
History
Summarize
Perspective
Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran.[10] Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under the same name in the United States.[11] In 2008, Medsn officially became Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a continuing medical education company based in the United States.[7][12]
In 2009, Indegene signed a master service agreement with six pharmaceutical companies.[6][13] The following year, Indegene acquired Canada-based Aptilon, a multichannel marketing firm, for $4 million.[14] The company subsequently acquired Atlanta-based Total Therapeutic Management in 2014.[15]
In September 2019, Indegene acquired London-based consulting company, DT Associates, for $10 million.[16]
In February 2021, the Carlyle Group and Brighton Park Capital invested $200 million in Indegene.[17] In August 2021, Indegene acquired Medical Marketing Economics (MME), an American market access and pricing strategy company, for $10 million.[18]
Indegene went public in May 2024 with an initial public offering, raising ₹1,842 crore (US$220 million). It listed on the BSE and the NSE.[19][20]
Operations
Indegene has offices in India, the United States, the European Union, and Asia-Pacific.[21][12]
In 2011 and 2012, The Economic Times named Indegene one of the best companies to work for in the Professional Services industry.[22]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.